Study Description: The purpose of this study is to test a possible new treatment for schizophrenia and schizoaffective disorder using tocilizumab versus placebo in a 12 week trial to determine its effects on symptoms, especially cognition.
Principal Investigator: Brian Miller
Eligibility Criteria: Males and Females between ages 18 and 55 DIagnosis of Schizophrenia or Schizoaffective Disorder No Psychiatric hospitalizations in the past 3 months
Compensation: Yes, subjects will be compensated.
Compensation Explanation: Subjects will receive a check in the amount of: $50 for completing the first (Screening) visit, $100 for completing the second visit (Baselinevisit and first Tocilizumab infusion), $50 for completing the third visit (2 week follow-up), $100 for completing the fourth visit (4 week follow up and second Tocilizumab infusion), $100 for completing the fifth visit (8 weekfollow-up and third Tocilizumab infusion), and $100 for completing the sixth visit (12 week follow-up) in this study. Subjects will be responsible for the costs of transportation to participate in the study.
If you don't see specific studies that interest you, please submit your contact information for future studies.